from Economic Times
MUMBAI: Lupin has received approval from the Drugs Controller General (India) to conduct a combined phase-IIb/III clinical trial for its herbal anti-psoriasis compound.

The botanical drug product is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis. The approval comes after the company successfully completed an initial phase II clinical trial in which it evaluated the oral drug product in different lower doses.

The company intends to immediately begin a combined phase IIB/ III clinical trial with higher doses in close to 10 centers across the nation. The total market for psoriasis is estimated to be more than $2 billion. Lupin also has three other new chemical entities in various stages of clinical trials.